Subscribe To
TCRX / TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
TCRX News
By Zacks Investment Research
October 12, 2023
TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why
TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal
By Zacks Investment Research
August 16, 2023
TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know
TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal
By Zacks Investment Research
August 10, 2023
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compare more_horizontal
By GlobeNewsWire
May 17, 2023
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation more_horizontal
By Zacks Investment Research
May 10, 2023
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compare more_horizontal
By PennyStocks
May 10, 2023
3 Top Strategies for Maximizing Penny Stock Profits Right Now
Use these strategies to maximize your penny stocks profits The post 3 Top Strategies for Maximizing Penny Stock Profits Right Now appeared first on Pe more_horizontal
By Market Watch
May 9, 2023
TScan Therapeutics stock soars after Amgen collaboration on Crohn's disease treatment that could bring in more than $500 million
Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration wi more_horizontal
By Benzinga
January 24, 2022
FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies
The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies p more_horizontal